A389030 Stock Overview
A bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GENINUS Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,365.00 |
| 52 Week High | ₩2,765.00 |
| 52 Week Low | ₩1,209.00 |
| Beta | 0.61 |
| 1 Month Change | 3.02% |
| 3 Month Change | -13.28% |
| 1 Year Change | -48.10% |
| 3 Year Change | -67.88% |
| 5 Year Change | n/a |
| Change since IPO | -69.44% |
Recent News & Updates
Is GENINUS (KOSDAQ:389030) Using Debt In A Risky Way?
Dec 10
Is GENINUS (KOSDAQ:389030) A Risky Investment?
Aug 07Is GENINUS (KOSDAQ:389030) In A Good Position To Invest In Growth?
Apr 12Shareholder Returns
| A389030 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.5% | -0.004% | -0.04% |
| 1Y | -48.1% | 8.4% | -12.2% |
Return vs Industry: A389030 underperformed the KR Biotechs industry which returned 9.5% over the past year.
Return vs Market: A389030 underperformed the KR Market which returned -11.6% over the past year.
Price Volatility
| A389030 volatility | |
|---|---|
| A389030 Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A389030 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A389030's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 75 | Woongyang Park | kr-geninus.com |
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea. It offers CancerSCAN, an NGS-based cancer genome diagnosis solution; LiquidSCAN, a liquid biopsy NGS test; and Celinus, a single-cell analysis solution for ultra-precise genome analysis. The company also provides HealthSCAN, a genetic test service; WithMe, a service that analyzes gut bacteria characteristics related to the risk of chronic diseases; and OncoSTATION, an automated clinical genome information analysis solution.
GENINUS Inc. Fundamentals Summary
| A389030 fundamental statistics | |
|---|---|
| Market cap | ₩45.53b |
| Earnings (TTM) | -₩12.07b |
| Revenue (TTM) | ₩6.71b |
6.8x
P/S Ratio-3.8x
P/E RatioIs A389030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A389030 income statement (TTM) | |
|---|---|
| Revenue | ₩6.71b |
| Cost of Revenue | ₩7.18b |
| Gross Profit | -₩473.58m |
| Other Expenses | ₩11.59b |
| Earnings | -₩12.07b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -361.85 |
| Gross Margin | -7.06% |
| Net Profit Margin | -179.98% |
| Debt/Equity Ratio | 17.8% |
How did A389030 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:23 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GENINUS Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|